Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Enveric Biosciences Inc (ENVB)

Enveric Biosciences Inc (ENVB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Enveric Biosciences (NASDAQ: ENVB) Obtains Notice of Allowance For a U.S. Patent Covering Its Innovative Psilocin Prodrug, EB-373 Spotlight Growth - Thu May 18, 2023

Enveric Biosciences, Inc. (NASDAQ: ENVB) is engaged as a biotechnology company, which focused on the research and development of innovative

ENVB : 0.3499 (-1.44%)
Enveric Biosciences Celebrates and Supports 2023 Mental Health Awareness Month Business Wire - Tue May 2, 2023

Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression,...

ENVB : 0.3499 (-1.44%)
Enveric Biosciences to Participate in Benzinga Psychedelics Capital Conference Business Wire - Mon Apr 10, 2023

Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression,...

ENVB : 0.3499 (-1.44%)
Enveric Biosciences Reports Fourth Quarter and Year-End 2022 Corporate and Financial Results Business Wire - Mon Apr 3, 2023

Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression,...

ENVB : 0.3499 (-1.44%)
Enveric Biosciences Selects Australian CRO, Avance Clinical, in Preparation for Phase 1 Study of EB-373 Business Wire - Thu Mar 23, 2023

Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression,...

ENVB : 0.3499 (-1.44%)
Enveric Biosciences Establishes Australia-based Subsidiary to Accelerate its Lead Psilocin Prodrug Program Targeting Mental Health Indications Business Wire - Tue Mar 21, 2023

Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression,...

ENVB : 0.3499 (-1.44%)
Enveric Biosciences Announces Bioproduction Platform Using Novel Cane Toad Enzyme for Psychedelic-Inspired Drug Discovery Business Wire - Tue Mar 14, 2023

Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression,...

ENVB : 0.3499 (-1.44%)
Enveric Biosciences Appoints Kevin Coveney as Chief Financial Officer, and Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Business Wire - Tue Feb 28, 2023

Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression,...

ENVB : 0.3499 (-1.44%)
Enveric Biosciences Names Lynn Gallant Vice President, Clinical Operations, and Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Business Wire - Thu Feb 23, 2023

Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression,...

ENVB : 0.3499 (-1.44%)
Enveric Biosciences to Present at the Gravitas Securities Inc. 6th Annual Growth Conference Business Wire - Wed Feb 22, 2023

Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression,...

ENVB : 0.3499 (-1.44%)

Barchart Exclusives

Stocks Slip Before the Open on Nvidia’s Disappointing Forecast and Ukraine Jitters, U.S. Economic Data on Tap Barchart - 53 minutes ago
December S&P 500 E-Mini futures (ESZ24) are down -0.31%, and December Nasdaq 100 E-Mini futures (NQZ24) are down -0.43% this morning as a disappointing revenue forecast from Nvidia and concerns about escalating Russia-Ukraine tensions dampened sentiment. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot